Regeneron PharmaceuticalsSTU:RGO -0.44%83 Altman Z2-Score is 9.35 as of Jul. 05, 2026, which is 2% above its 10-year median of 9.19. GuruFocus rates STU:RGO with a GF Score™ of 83/100 and a GF Value™ of €784.23 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,391 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 81.02% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Regeneron Pharmaceuticals has a Altman Z2-Score of 9.35, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Regeneron Pharmaceuticals's Altman Z2-Score or its related term are showing as below:
STU:RGO'
s Altman Z2-Score Range Over the Past 10 Years
Min: 5.78 Med: 9.19 Max: 10.87
Current: 9.36
During the past 13 years, Regeneron Pharmaceuticals's highest Altman Z2-Score was 10.87. The lowest was 5.78. And the median was 9.19.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RGO vs ALNY, RVMD, ONC: Altman Z2-Score Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Regeneron Pharmaceuticals (STU:RGO) has a Altman Z2-Score of 9.35 as of Jul. 05, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Regeneron Pharmaceuticals and its competitors. This is near median its historical median of 9.19. Over the past decade, Regeneron Pharmaceuticals' Altman Z2-Score has ranged from 5.78 to 10.87. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #264 out of 1391 companies in the Biotechnology industry, placing it in the top 19%.
Is Regeneron Pharmaceuticals' Altman Z2-Score too high?
Regeneron Pharmaceuticals' current Altman Z2-Score of 9.35 is near median its 10-year median of 9.19. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 10.87. Based on the distribution chart, Regeneron Pharmaceuticals ranks #264 out of 1391 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Altman Z2-Score compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #264 out of 1391 companies for Altman Z2-Score. This places Regeneron Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own Altman Z2-Score has ranged from 5.78 to 10.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Altman Z2-Score is 9.35, which is near median its own 10-year median of 9.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €784.23, compared to a current price of €569.20 — trading 27.4% below its estimated fair value. The current Altman Z2-Score is 9.35, which is near median its 10-year median of 9.19. Regeneron Pharmaceuticals' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Altman Z2-Score is 9.35 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €569.20 is trading 27.4% below its estimated GF Value™ of €784.23.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for STU:RGO:
Altman Z2-Score: 9.35 (near median its 10-year median of 9.19)
GF Value™: €784.23 vs. price of €569.20 (27.4% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
83GF Score
Get the complete analysis for STU:RGO
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
